Product Reports Resources Pricing Login Book a demo
COMPANY PROFILE

Promentis Pharmaceuticals

Request full access

Developing antipsychotic drugs to treat schizophrenia

Milwaukee, United StatesFounded 2006Biotech & Life Sciences

About Promentis Pharmaceuticals

Promentis Pharmaceuticals, Inc. is a privately held biopharmaceutical company focused on the discovery and development of first-in-class therapies for the treatment of neuropsychiatric disorders. The company operates in the biopharmaceutical sector, specifically targeting central nervous system (CNS) disorders. Promentis develops novel oral compounds that engage System xc, a CNS target for diverse psychiatric conditions. The company's business model revolves around research and development (R&D) of these innovative therapies, aiming to bring them to market through clinical trials and regulatory approval. Revenue generation is primarily expected from the commercialization of these therapies, either through direct sales or partnerships with larger pharmaceutical companies. Promentis serves patients suffering from neuropsychiatric disorders, healthcare providers, and the broader medical community. The market it operates in is highly specialized and competitive, with a focus on addressing unmet medical needs in CNS disorders.

Source: Dealroom company data

At a glance

Status
Operational
Employees
5
Open positions
None listed
Dealroom signal
81.3/100
Industry
Health
Sub-industry
BioTechnology
Sector
Biotechnology, Spinout, Biotech and Pharma, DT and LS, science-based
Business model
Manufacturing
Client focus
B2C

Funding history

10 recorded events

Company financing events and reported valuations.

Deal typeDateAmountValuationInvestorsSource
EARLY VCOther financing Dec 2019 $2.5M $10M Undisclosed —
GROWTH EQUITY VCOther financing Sep 2017 $18M — Undisclosed —
Showing the latest 2 of 10 recorded eventsBook a demo for the full funding history →

Growth signals

Promentis Pharmaceuticals website traffic

Latest recorded traffic for Promentis Pharmaceuticals is 1.3K monthly website visits, up 78.1% over the last three months. Promentis Pharmaceuticals's team grew 0% over the past year.

Latest monthly visits1.3K 3-month web change+78.1% 1-year team growth0%
Summary metrics are public; monthly history is available with a demoCompare with peers →

Similar companies

Closest operating peers by Dealroom taxonomy

Company identity and context are open; selected comparison metrics preview what is available on the platform.

Showing 8 of the closest matchesCompare every metric →

Investments and acquisitions

Capital deployed

Recent portfolio relationships for companies that also act as investors or acquirers.

Promentis Pharmaceuticals in the Milwaukee ecosystem

Live from Dealroom

The Promentis Pharmaceuticals office with the hot startups, most funded companies and investors around it. Hover or tap a pin.

Loading the map…

Dealroom maps whole ecosystems like this one for cities, regions and governments. See the ecosystem platform →

Investors

10 investors on the cap table

From Dealroom's funding and investor records, grouped by the round each investor first entered.

Seed2 investors entered at this stage

  • Golden Angels Investors
  • National Institutes of Health

Series A1 investor entered at this stage

  • Black Horse Investments

Series B and later4 investors entered at this stage

Other known investors3 additional known investors

  • Marquette University
  • University of Montana
  • University of Wisconsin-Milwaukee
Team profiled 5 named & role-tagged
Founders Hidden — book a demo/100 quality score
Key operators 3 quality Hidden — book a demo/100
Potential founders Hidden — book a demo likely future founders
Startup mafia Hidden — book a demo alumni-founded startups
Talent movements Hidden — book a demo in · Hidden — book a demo out past 12 months

Source: Dealroom Talent Intelligence.

Global footprint

Workforce and web traffic by country
Workforce by country
1 countries with
team presence
🇺🇸 United States100%
1 country shown

Market sentiment

Posts on X, past 7 days

An AI-synthesised read of the highest-engagement posts about Promentis Pharmaceuticals on X, ranked by likes and reposts, corporate channels excluded.

Reading the room on X — pulling top posts and synthesizing themes…

Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour

See Promentis Pharmaceuticals’s full profile on Dealroom

Request a free trial to see the complete deal history, financials, people graph and growth signals.

Takes under a minute. Already use Dealroom? Log in.